Want to join the conversation?
Liav Abraham of Citigroup asks for an update on the generics business environment. $ENDP said it does not expect major changes from the Teva deal. The company has four large consortiums representing around 90% of the business but it will still face competition from Teva. $ENDP will focus on bringing new products to the marketplace.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.